India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems
26th March 2025 Uncategorised 0Aspen Biopharma Labs was hit with a warning letter from the FDA outlining multiple issues at an API facility in India, including poor building design that could lead to drug contamination.
More: India's Aspen Biopharma Labs hit with FDA warning letter citing infrastructure, contamination and records problems
Source: fierce
